• 1
    World Health Organization. Hepatitis B vaccines WHO position paper. Wkly Epidemiol Rec 2004; 79: 255263.
  • 2
    World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988; 66: 443455.
  • 3
    Poovorawan Y, Chongsrisawat V, Tangkijvanich P. Problems and prevention of viral hepatitis in Thailand. J Med Assoc Thai 2001; 84(Suppl 1): S18S25.
  • 4
    Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 13561361.
  • 5
    Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20: 37393743.
  • 6
    Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 62666273.
  • 7
    Chongsrisawat V, Yoocharoen P, Theamboonlers A et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006; 11: 14961502.
  • 8
    Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006; 28: 126135.
  • 9
    Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol (Berl) 2005; 194: 163168.
  • 10
    Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008; 9: 507510.
  • 11
    Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007; 5: 7984.
  • 12
    Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261: 32783281.
  • 13
    Poovorawan Y, Sanpavat S, Pongpunlert W et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990; 8(Suppl): S56S59.
  • 14
    Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed 1997; 77: F47F51.
  • 15
    Poovorawan Y, Sanpavat S, Pongpunglert W et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992; 11: 816821.
  • 16
    Chinchai T, Chirathaworn C, Praianantathavorn K et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18–20 years after neonatal immunization. Viral Immunol 2009; 22: 125130.
  • 17
    Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28: 730736.
  • 18
    Lopez VA, Bourne EJ, Lutz MW, Condreay LD. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 2002; 40: 19721976.
  • 19
    Su FH, Cheng SH, Li CY et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 80858090.
  • 20
    Alfaleh F, Alshehri S, Alansari S et al. Long-term protection of hepatitis B vaccine in Saudi Arabia 18 years after vaccination. J Infect 2008; 57: 404409.
  • 21
    van der Sande MA, Waight PA, Mendy M et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2007; 2: e753.
  • 22
    Kao JT, Wang JH, Hung CH et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009; 27: 18581862.
  • 23
    But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26: 65876591.